Mirae Asset Global ETFs Holdings’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$603K Buy
40,646
+2,494
+7% +$34.6K ﹤0.01% 1903
2026
Q1
$548K Buy
38,152
+5,743
+18% +$91.7K ﹤0.01% 1848
2025
Q4
$248K Buy
32,409
+4,884
+18% +$38.5K ﹤0.01% 2248
2025
Q3
$203K Sell
27,525
-1,136
-4% -$5.81K ﹤0.01% 2311
2025
Q2
$115K Buy
+28,661
New +$104K ﹤0.01% 2540

Other funds holding CRVS

Mirae Asset Global ETFs Holdings's CRVS Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Corvus Pharmaceuticals (CRVS) stake by 6.5% in Q2 2026, buying an estimated $34.6K and bringing the position to 40,646 shares worth $603K. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Mirae Asset Global ETFs Holdings first reported a position in CRVS in Q2 2025 and has held it in 5 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 40,646 shares of Corvus Pharmaceuticals worth $603K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 2,494 Corvus Pharmaceuticals shares in Q2 2026, an estimated $34.6K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1903 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.